New insights into the mechanisms underlying vascular and cardiac effects of urocortin

Current Vascular Pharmacology

Volumn 11, Issue 4, 2013, Pages 457-464

  Díaz, Ignacio ^a   Smani, Tarik ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Cardioprotection; Positive inotropism; Urocortin; Vascular smooth muscle relaxation

Indexed keywords

CALCIUM; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; UROCORTIN;

CELL DEATH; HEART CONTRACTION; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART PROTECTION; HUMAN; INOTROPISM; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION;

ANIMALS; CALCIUM; CARDIOVASCULAR PHYSIOLOGICAL PROCESSES; CELL DEATH; HUMANS; MITOCHONDRIA; MUSCLE CONTRACTION; MYOCARDIAL REPERFUSION INJURY; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; UROCORTINS; VASODILATION;

EID: 84882756993     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311040009     Document Type: Review

References (76)

1. Katugampola S, Davenport A. Emerging roles for orphan Gprotein-coupled receptors in the cardiovascular system. Trends Pharmacol Sci 2003; 24: 30-5.
2. Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropinreleasing factor. Nature 1995; 378:287-92
3. Calderon-Sanchez E, Delgado C, Ruiz-Hurtado G, et al. Urocortin induces positive inotropic effect in rat heart. Cardiovasc Res 2009; 83: 717-25
4. Smani T, Calderon-Sanchez E, Gómez-Hurtado N, et al. Mechanisms underlying the activation of L-type calcium channels by urocortin in rat ventricular myocytes. Cardiovasc Res 2010; 87: 459-66
5. Lawrence KM, Latchman DS. The Urocortins: mechanisms of cardioprotection and therapeutic potential. Mini Rev Med Chem 2006; 6:1119-26.
6. Charles CJ, Rademaker MT, Richards AM. Urocortins: putative role in cardiovascular disease. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 43-7
7. Venkatasubramanian S, Newby DE, Lang NN. Urocortins in heart failure. Biochem Pharmacol 2010; 80: 289-96
8. Vale W, Spiess J, Rivier C, et al. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981; 213: 1394-7
9. Donaldson CJ, Sutton SW, Perrin MH, et al. Cloning and characterization of human urocortins. Endocrinology 1996; 137: 2167-70
10. Lewis K, Li C, Perrin MH, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 2001; 98: 7570-5.
11. Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 2001; 98: 2843-8.
12. Grace CR, Perrin MH, Cantle JP, et al. Common and divergent structural features of a series of corticotrophin releasing factor related peptides. J Am Chem Soc 2007; 129: 16102-14.
13. Vamvakopoulos NC, Sioutopoulou TO. Human corticotropinreleasing hormone receptor gene (CRHR) is located on the long arm of chromosome 17 (17q12-qter). Chromosome Res 1994; 2: 471-3.
14. Iino K, Sasano H, Oki Y, et al. Urocortin expression in the human central nervous system. Clin Endocrinol 1999; 50: 107-14.
15. Takahashi K, Totsune K, Sone M, et al. Regional distribution of urocortin-like immunoreactivity and expression of urocortin mRNA in the human brain. Peptides 1998; 19: 643-7.
16. Nishikimi T, Miyata A, Horio T, et al. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 2000; 279: H3031-9
17. Kimura Y, Takahashi K, Totsune K, et al. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 2002; 87: 340-6
18. Okosi A, Brar B K, Chan M, et al. Expression and protective effects of urocortin in cardiac myocytes. Neuropeptides 1998; 32: 167-71.
19. Kozicz T, Arimura A. Distribution of urocortin in the rat's gastrointestinal tract and its colocalization with tyrosine hydroxylase. Peptides 2002; 23: 515-21.
20. Muramatsu Y, Fukushima K, Lino K, et al. Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa. Peptides 2000; 21: 1799-809.
21. Chen A, Blount A, Vaughan J, et al. Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in CRF1 and CRF2-null mice and regulation by glucocorticoids. Endocrinology 2004; 145: 2445-57.
22. Li C, Vaughan J, Sawchenko PE, et al. Urocortin III inmunoreactive projections in rat brain: partial overlap with sites of type 2 corticotropin-releasing factor receptor expression. J Neurosci 2002; 22: 991-1001.
23. Lewis K, Li C, Perrin MH, et al. Identification of Urocortin III, an additional member of the corticotrophin-releasing factor family with high affinity for the CRFR2 receptor. Proc Natl Acad Sci USA 2001; 98: 7570-5.
24. Davis ME, Pemberton CJ, Yandle TG, et al. Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab 2004; 89: 1402-9.
25. Davis ME, Pemberton CJ, Yandle TG, et al. Effect of Urocortin 1 infusion in human with stable congestive cardiac failure. Clin Sci 2005; 109: 381-8.
26. Davis ME, Pemberton CJ, Yandle TG, et al. Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. J Am Coll Cardiol 2007; 49: 461-71.
27. Rademaker MT, Cameron VA, Charles CJ, et al. Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 2006; 27: 2088-98.
28. Chen R, Lewis KA, Perrin MH, et al. Expression cloning of a human corticotropin-releasing factor receptor. Proc Natl Acad Sci USA 1993; 90: 8967-71.
29. Lovenberg TW, Liaw CW, Grigoriadis DE, et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 1995; 92: 836-40.
30. Vamvakopoulos NC, Siotopoulou TO. Human corticotropinreleasing hormone receptor gene is located on the long arm of chromosome 17. Chromosome Res 1994; 2: 471-73
31. Meyer AH, Ullmer C, Schmuck K, et al. Localization of the human CRF2 receptor to 7p21-p15 by radiation hybrid mapping and FISH analysis. Genomics 1997; 40: 189-90
32. Hillhouse EW, Grammatopoulus DK. The molecular mechanism underlying the regulation of the biological activity of corticotrophin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 2006; 27: 260-86.
33. Van Pett K, Viau V, Bittencourt JC, et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 2000; 428: 191-212.
34. Perrin M, Donaldson C, Chen R, et al. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci USA 1995; 92: 2969-73.
35. Mazur AW, Wang F, Tcheiner M, et al. Determinants of corticotroping-releasing factor. Receptor selectivity of corticotropin releasing factor related peptides. J Med Chem 2004; 47: 3450-54
36. Jahn O, Tezval H, van Werven L, et al. Three amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity. Neuropharmacology 2004; 47: 233-42.
37. Baigent SM, Lowry PJ. mRNA expression profiles for corticotrophin releasing factor (CRF), urocortin, CRF receptors and CRFbinding protein in peripheral rat tissues. J Mol Endocrinol 2000; 25: 43-52.
38. Wiley KE, Davenport AP. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol 2004; 143: 508-14.
39. Bale TL, Hoshijima M, Gu Y, et al. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 2004; 101: 3697-702.
40. Chen J, Tao J, Zhang R, et al. Urocortin inhibits mesenteric arterial remodeling in spontaneously hypertensive rats. Peptides 2009; 30: 1117-23.
41. Huang Y, Chan FL, Lau CW, et al. Urocortin-induced endothelium-dependent relaxation of rat coronary artery: role of nitric oxide and K+ channels. Br J Pharmacol 2002; 135: 1467-76.
42. Schilling L, Kanzler C, Schmiedek P, et al. Characterization of the relaxant action of urocortin, a new peptide related to corticotropinreleasing factor in the rat isolated basilar artery. Br J Pharmacol 1998; 125: 1164-71.
43. Lubomirov LT, Reimann K, Metzler D, et al. Urocortin-induced decrease in Ca2+ sensitivity of contraction in mouse tail arteries is attributable to cAMP-dependent dephosphorylation of MYPT1 and activation of myosin light chain phosphatase. Circ Res 2006; 98: 1159-67.
44. Smani T, Domínguez-Rodríguez A, Hmadcha A, et al. Role of Ca2+-independent phospholipase A2 and store-operated pathway in urocortin-induced vasodilatation of rat coronary artery. Circ Res 2007; 101: 1194-203.
45. Smani T, Calderon E, Rodriguez-Moyano M, et al. Urocortin-2 induces vasorelaxation of coronary arteries isolated from patients with heart failure. Clin Exp Pharmacol Physiol 2011; 38: 71-6.
46. Chen ZW, Huang Y, Yang Q, et al. Urocortin-induced relaxation in the human internal mammary artery. Cardiovasc Res 2005; 65: 913-20.
47. Leitch IM, Boura AL, Botti C, et al. Vasodilator actions of urocortin and related peptides in the human perfused placenta in vitro. J Clin Endocrinol Metab 1998; 83: 4510-3.
48. Sanz E, Monge L, Fernandez N, et al. Relaxation by urocortin of human saphenous veins. Br J Pharmacol 2002; 136: 90-4.
49. Schilling L, Kanzler C, Schmiedek P, et al. Characterization of the relaxant action of urocortin, a new peptide related to corticotropinreleasing factor in the rat isolated basilar artery. Br J Pharmacol 1998; 125: 1164-71.
50. Lubomirov L, Gagov H, Petkova-Kirova P, et al. Urocortin relaxes rat tail arteries by a PKA-mediated reduction of the sensitivity of the contractile apparatus for calcium. Br J Pharmacol 2001; 134: 1564-70.
51. Huang Y, Chan FL, Lau CW, et al. Roles of cyclic AMP and Ca2+-activated K+ channels in endothelium-independent relaxation by urocortin in the rat coronary artery. Cardiovasc Res 2003; 57: 824-33.
52. Chu CP, Qiu DL, Kato K, et al. Central stresscopin modulates cardiovascular function through the adrenal medulla in conscious rats. Regul Pept 2004; 145: 2445-57.
53. Parkes DG, Vaughan J, Rivier J, et al. Cardiac inotropic actions of urocortins in conscious sheep. Am J Phisiol Heart Circ Physiol 1997; 272: H2115-22.
54. Yang LZ, Kockskämper J, Heinzel FR, et al. Urocortin II enhances contractility in rabbit ventricular myocytes via CRF(2) receptormediated stimulation of protein kinase A. Cardiovasc Res 2006; 69: 402-11.
55. Brar BK, Jonassen AK, Egorina EM, et al. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 2004; 145: 24-35.
56. Knight RA, Chen-Scarabelli C, Yuan Z, et al. Cardiac release of urocortin precedes the occurrence of irreversible myocardial damage in the rat heart exposed to ischemia/reperfusion injury. FEBS Lett 2008; 582: 984-90.
57. Brar BK, Jonassen AK, Stephanou A, et al. Urocortin protects against ischemia and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 2000; 275: 8508-14.
58. 2+ /calmodulin-dependent protein kinases mediate inotropic, lusitropic and arrhythmogenic effects of urocortin 2 in mouse ventricular myocytes. Br J Pharmacol 2011; 162: 544-56.
59. Lawrence KM, Scarabelli TM, Turtle L, et al. Urocortin protects cardiac myocytes from ischemia/reperfusión injury by attenuating calcium-sensitive phospholipase A2 gene expression. FASEB J 2003; 17: 2313-5.
60. Scarabelli T, Knight R. Urocortins: take them to heart. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 335-42.
61. Boonprasert P, Lailerd N, Chattipakorn N. Urocortins in heart failure and ischemic heart disease. Int J Cardiol 2008; 127: 307-12.
62. Lawrence KM, Kabir AM, Bellahcene M, et al. Cardioprotection mediated by Urocortin is dependent on PKC-epsilon activation. FASEB J 2005; 19: 831-3
63. Scarabelli TM, Pasini E, Stephanou A, et al. Urocortin promotes hemodynamic and bioenergetics recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. J AM Coll Cardiol 2002; 40: 155-61
64. Calderón-Sánchez EM, Ruiz-Hurtado G, Smani T, et al. Cardioprotective action of urocortin in postconditioning involves recovery of intracellular calcium handling. Cell Calcium 2011; 50: 84-90.
65. Lawrence KM, Townsend PA, Davidson SM, et al. The cardioprotective effect of urocortin during ischaemia/reperfusion involves the prevention of mitochondrial damage. Biochem Biophys Res Commun 2004; 321: 479-86.
66. Townsend PA, Davidson SM, Clarke SJ, et al. Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress. Am J Physiol Heart Circ Physiol 2007; 293: H928-38.
67. Simonis G, Honold J, Schwarz K, et al. Regulation of the isozymes of protein kinase C in the surviving rat myocardium after myocardial infarction: distinct modulation for PKC-alpha and for PKC-delta. Basis Res Cardiol 2002; 97: 223-31
68. Bonni A, Brunet A, West AE, et al. Cell survival promoted by the Ras-MAPK signaling pathway by transcription dependent and in-dependent mechanisms. Science 1999; 286: 1358-62.
69. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838-49.
70. Brar BK, Stephanou A, Knight R, et al. Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cadiol 2002; 34: 483-92.
71. Barry SP, Lawrence KM, McCormick J, et al. New targets of urocortin-mediated cardioprotection. J Mol Endocrinol 2010; 45: 69-85.
72. Brar BK, Railson J, Stephanou A, et al. Urocortin increases the expression of heat shock protein 90 in rat cardiac myocytes in a MEK1/2-dependent manner. J Endocrinol 2002; 172: 283-93.
73. Janjua S, Lawrence KM, Ng LL, et al. The cardioprotective agent urocortin induces expression of CT-1. Cardiovasc Toxicol 2003; 3: 255-62.
74. Lawrence KM, Chanalaris A, Scarabelli T, et al. K(ATP) channel gene expression is induced by urocortin and mediates its cardioprotective effect. Circulation 2002; 106: 1556-62.
75. Steer SA, Wirsig KC, Creer MH, et al. Regulation of membrane associated iPLA2 activity by a novel PKC isoform in ventricular myocytes. AM J Physiol Cell Physiol 2001; 283: C1621-6.
76. Takatani-Nakase T, Takahashi K. Cardioprotective activity of urocortin by preventing caspase-independent, non-apoptotic death in cultured neonatal rat cardiomyocytes exposed to ischemia. Biochem Biophys Res Commun 2010; 402: 216-21.